Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 860

1.

Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation.

Petkovic J, Riddle A, Akl EA, Khabsa J, Lytvyn L, Atwere P, Campbell P, Chalkidou K, Chang SM, Crowe S, Dans L, Jardali FE, Ghersi D, Graham ID, Grant S, Greer-Smith R, Guise JM, Hazlewood G, Jull J, Katikireddi SV, Langlois EV, Lyddiatt A, Maxwell L, Morley R, Mustafa RA, Nonino F, Pardo JP, Pollock A, Pottie K, Riva J, Schünemann H, Simeon R, Smith M, Stein AT, Synnot A, Tufte J, White H, Welch V, Concannon TW, Tugwell P.

Syst Rev. 2020 Feb 1;9(1):21. doi: 10.1186/s13643-020-1272-5.

2.

Thresholds and innovation.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2020 Feb;118:A5-A7. doi: 10.1016/j.jclinepi.2020.01.003. No abstract available.

PMID:
32005448
3.

The effectiveness of substance use interventions for homeless and vulnerably housed persons:  A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder.

Magwood O, Salvalaggio G, Beder M, Kendall C, Kpade V, Daghmach W, Habonimana G, Marshall Z, Snyder E, O'Shea T, Lennox R, Hsu H, Tugwell P, Pottie K.

PLoS One. 2020 Jan 16;15(1):e0227298. doi: 10.1371/journal.pone.0227298. eCollection 2020.

4.

Can the Schwarz and Lalouch concept of differentiating between explanatory and pragmatic studies be useful for diagnostic test studies?

Tugwell P, Knottnerus JA.

J Clin Epidemiol. 2020 Jan;117:A6-A9. doi: 10.1016/j.jclinepi.2019.12.004. No abstract available.

PMID:
31924314
5.

A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder.

Dennis BB, Sanger N, Bawor M, Naji L, Plater C, Worster A, Woo J, Bhalerao A, Baptist-Mohseni N, Hillmer A, Rice D, Corace K, Hutton B, Tugwell P, Thabane L, Samaan Z.

Trials. 2020 Jan 6;21(1):30. doi: 10.1186/s13063-019-3995-y.

6.

"Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort:Methodological issues to avoid misinterpretation".

Tugwell P.

J Clin Epidemiol. 2019 Dec 25. pii: S0895-4356(19)31145-X. doi: 10.1016/j.jclinepi.2019.12.018. [Epub ahead of print] No abstract available.

PMID:
31883452
7.

Scope of outcomes in trials and observational studies of interventions targeting medication adherence in rheumatic conditions: a systematic review.

Kelly A, Crimston-Smith L, Tong A, Bartlett SJ, Bekker C, Christensen R, De Vera MA, de Wit M, Evans V, Gill M, March L, Manera K, Nieuwlaat R, Salmasi S, Scholte-Voshaar M, Singh JA, Sumpton D, Toupin-April K, Tugwell P, van den Bemt B, Verstappen S, Tymms K.

J Rheumatol. 2019 Dec 15. pii: jrheum.190726. doi: 10.3899/jrheum.190726. [Epub ahead of print]

PMID:
31839595
8.

Instruments that measure psychosocial factors related to vaccination: a scoping review protocol.

Kaufman J, Ryan R, Betsch C, Parkhill A, Shapiro G, Leask J, Menning L, Tugwell P, Costa DS, Danchin M, Rada G, Hill S.

BMJ Open. 2019 Dec 9;9(12):e033938. doi: 10.1136/bmjopen-2019-033938.

9.

Should the cost perspective be integrated in clinical guidelines?: On individual and societal perspectives in health research.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2019 Dec;116:A6-A8. doi: 10.1016/j.jclinepi.2019.10.009. No abstract available.

PMID:
31791533
10.

Engaging Patients and Other Non-Researchers in Health Research: Defining Research Engagement.

Frank L, Morton SC, Guise JM, Jull J, Concannon TW, Tugwell P; Multi Stakeholder Engagement (MuSE) Consortium.

J Gen Intern Med. 2020 Jan;35(1):307-314. doi: 10.1007/s11606-019-05436-2. Epub 2019 Nov 11.

PMID:
31713031
11.

Confounding obscures our view, effect modification is part of reality.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2019 Oct;114:v-vi. doi: 10.1016/j.jclinepi.2019.08.011. No abstract available.

PMID:
31570139
12.

Tai Chi for rheumatoid arthritis.

Mudano AS, Tugwell P, Wells GA, Singh JA.

Cochrane Database Syst Rev. 2019 Sep 25;9:CD004849. doi: 10.1002/14651858.CD004849.pub2.

PMID:
31553478
13.

Comparison of bias adjustment methods in meta-analysis suggests that quality effects modeling may have less limitations than other approaches.

Stone JC, Glass K, Munn Z, Tugwell P, Doi SAR.

J Clin Epidemiol. 2020 Jan;117:36-45. doi: 10.1016/j.jclinepi.2019.09.010. Epub 2019 Sep 18.

PMID:
31541691
14.

Trial recruitment a continuing challenge.

Tugwell P, Knottnerus A.

J Clin Epidemiol. 2019 Sep;113:vi-viii. doi: 10.1016/j.jclinepi.2019.07.018. No abstract available.

PMID:
31470965
15.

Comprehensive evidence and clinical judgment.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2019 Aug;112:v-vi. doi: 10.1016/j.jclinepi.2019.07.004. No abstract available.

PMID:
31376839
16.

Introduction.

March L, Richards B, Gill M, Brooks PM, Shea BJ, Beaton DE, Maxwell LJ, Tunis SR, Grosskleg S, Tugwell P.

J Rheumatol. 2019 Aug;46(8):962-968. doi: 10.3899/jrheum.190105. No abstract available.

PMID:
31371663
17.

Taking an integrated knowledge translation approach in research to develop the CONSORT-Equity 2017 reporting guideline: an observational study.

Jull J, Graham ID, Kristjansson E, Moher D, Petkovic J, Yoganathan M, Tugwell P, Welch VA; Members of the CONSORT-Equity 2017 and Boston Equity Symposium.

BMJ Open. 2019 Jul 30;9(7):e026866. doi: 10.1136/bmjopen-2018-026866.

18.

Patient and caregiver priorities for medication adherence in gout, osteoporosis and rheumatoid arthritis: nominal group technique.

Kelly A, Tymms K, de Wit M, Bartlett SJ, Cross M, Dawson T, De Vera M, Evans V, Gill M, Hassett G, Lim I, Manera K, Major G, March L, O'Neill S, Scholte-Voshaar M, Sinnathurai P, Sumpton D, Teixeira-Pinto A, Tugwell P, van den Bemt B, Tong A.

Arthritis Care Res (Hoboken). 2019 Jul 19. doi: 10.1002/acr.24032. [Epub ahead of print]

PMID:
31325214
19.

The scope and consistency of outcomes reported in trials in patients with systemic sclerosis.

Sumpton D, Bigot A, Sautenet B, Craig JC, Hassett G, Thakkar V, Tugwell P, Tong A.

Arthritis Care Res (Hoboken). 2019 Jul 15. doi: 10.1002/acr.24027. [Epub ahead of print]

PMID:
31309737
20.

Letter re: stratification by quality is not recommended in meta-analysis.

Stone J, Gurunathan U, Glass K, Munn Z, Tugwell P, Doi SAR.

J Clin Epidemiol. 2019 Nov;115:172-174. doi: 10.1016/j.jclinepi.2019.06.004. Epub 2019 Jun 7. No abstract available.

PMID:
31280932
21.

Should the fragility index be routinely reported for systematic reviews?

Tugwell P, Knottnerus A.

J Clin Epidemiol. 2019 Jul;111:v-vi. doi: 10.1016/j.jclinepi.2019.05.008. No abstract available.

PMID:
31178040
22.

Tramadol for osteoarthritis.

Toupin April K, Bisaillon J, Welch V, Maxwell LJ, Jüni P, Rutjes AW, Husni ME, Vincent J, El Hindi T, Wells GA, Tugwell P.

Cochrane Database Syst Rev. 2019 May 27;5:CD005522. doi: 10.1002/14651858.CD005522.pub3.

PMID:
31132298
23.

Inadequate comparators produce misleading results - the importance of good comparison practice.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2019 Jun;110:v-vi. doi: 10.1016/j.jclinepi.2019.04.010. No abstract available.

PMID:
31103071
24.

A unified framework for bias assessment in clinical research.

Stone JC, Glass K, Clark J, Munn Z, Tugwell P, Doi SAR.

Int J Evid Based Healthc. 2019 May 10. doi: 10.1097/XEB.0000000000000165. [Epub ahead of print]

PMID:
31094882
25.

Assessing evidence of interventions addressing inequity among migrant populations: a two-stage systematic review.

Yadee J, Bangpan M, Thavorn K, Welch V, Tugwell P, Chaiyakunapruk N.

Int J Equity Health. 2019 May 6;18(1):64. doi: 10.1186/s12939-019-0970-x.

26.

Need for greater transparency in documenting informed consent.

Tugwell P, Knottnerus JA.

J Clin Epidemiol. 2019 May;109:v-vii. doi: 10.1016/j.jclinepi.2019.04.004. No abstract available.

PMID:
31056106
27.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 Sep;46(9):1173-1178. doi: 10.3899/jrheum.190196. Epub 2019 May 1.

PMID:
31043547
28.
29.

WITHDRAWN: Interdental brushing for the prevention and control of periodontal diseases and dental caries in adults.

Poklepovic Pericic T, Worthington HV, Johnson TM, Sambunjak D, Imai P, Clarkson JE, Tugwell P.

Cochrane Database Syst Rev. 2019 Apr 24;4:CD009857. doi: 10.1002/14651858.CD009857.pub3. Review.

PMID:
31017680
30.

WITHDRAWN: Flossing for the management of periodontal diseases and dental caries in adults.

Sambunjak D, Nickerson JW, Poklepovic Pericic T, Johnson TM, Imai P, Tugwell P, Worthington HV.

Cochrane Database Syst Rev. 2019 Apr 23;4:CD008829. doi: 10.1002/14651858.CD008829.pub3. Review.

PMID:
31013348
31.

Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

de Wit M, Cooper C, Tugwell P, Bere N, Kirwan J, Conaghan PG, Roberts C, Aujoulat I, Al-Daghri N, Araujo de Carvalho I, Barker M, Bedlington N, Brandi ML, Bruyère O, Burlet N, Halbout P, Hiligsmann M, Jiwa F, Kanis JA, Laslop A, Lawrence W, Pinto D, Prieto Yerro C, Rabenda V, Rizzoli R, Scholte-Voshaar M, Vlaskovska M, Reginster JY.

Aging Clin Exp Res. 2019 Jul;31(7):905-915. doi: 10.1007/s40520-019-01193-8. Epub 2019 Apr 16. Review.

32.

Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018.

Chiarotto A, Kaiser U, Choy E, Christensen R, Conaghan PG, Cowern M, Gill M, de Wit M, Gargon E, Horgan B, Kirkham JJ, Simon LS, Singh JA, Tugwell P, Turk DC, Mease PJ.

J Rheumatol. 2019 Oct;46(10):1355-1359. doi: 10.3899/jrheum.181099. Epub 2019 Apr 1.

PMID:
30936284
33.

Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group.

Verstappen SMM, Lacaille D, Boonen A, Escorpizo R, Hofstetter C, Bosworth A, Leong A, Leggett S, Gignac MAM, Wallman JK, Ter Wee MM, Berghea F, Agaliotis M, Tugwell P, Beaton D.

J Rheumatol. 2019 Oct;46(10):1401-1405. doi: 10.3899/jrheum.181201. Epub 2019 Apr 1.

PMID:
30936275
34.

Research without good questions is a waste.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2019 Apr;108:vi-viii. doi: 10.1016/j.jclinepi.2019.02.017. No abstract available.

PMID:
30902351
35.

Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018.

Aydin SZ, Robson JC, Sreih AG, Hill C, Alibaz-Oner F, Mackie S, Beard S, Gul A, Hatemi G, Kermani TA, Mahr A, Meara A, Milman N, Shea B, Tómasson G, Tugwell P, Direskeneli H, Merkel PA.

J Rheumatol. 2019 Sep;46(9):1198-1201. doi: 10.3899/jrheum.181072. Epub 2019 Mar 15.

PMID:
30877212
36.

Human immunodeficiency virus testing and psychosocial outcomes: a scoping review protocol.

Ngobi JB, Pottie K, Leonard L, Tugwell P, Hoffman SJ, Welch V.

JBI Database System Rev Implement Rep. 2019 Aug;17(8):1616-1625. doi: 10.11124/JBISRIR-2017-003864.

PMID:
30864981
37.

Stepped wedge designs are coming of age in clinical epidemiology.

Tugwell P, Knottnerus JA.

J Clin Epidemiol. 2019 Mar;107:vi-viii. doi: 10.1016/j.jclinepi.2019.02.013. No abstract available.

PMID:
30857617
38.

The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future.

Flurey CA, Tugwell PS, Black RJ, Halls S, Page MJ, Robson JC, Sahbudin I, Siddle HJ, Sinnathurai P, Stok KS, Richards B.

J Rheumatol. 2019 Aug;46(8):1047-1052. doi: 10.3899/jrheum.181126. Epub 2019 Mar 1.

PMID:
30824659
39.

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.

Smith TO, Mansfield M, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, Christensen R, Guillemin F, Terwee CB, Williamson PR, Roos EM, Loeser RF, Schnitzer TJ, Kloppenburg M, Neogi T, Ladel CH, Kalsi G, Kaiser U, Buttel TW, Ashford AE, Mobasheri A, Arden NK, Tennant A, Hochberg MC, de Wit M, Tugwell P, Conaghan PG.

J Rheumatol. 2019 Aug;46(8):976-980. doi: 10.3899/jrheum.181066. Epub 2019 Mar 1.

PMID:
30824657
40.

Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis.

Lopez-Olivo MA, Negrón JB, Zogala RJ, Carmona L, Criner K, Goel N, Gonzalez-Lopez L, Ingegnoli F, Leong A, March L, Shea B, Strand V, Tugwell P, Westrich-Robertson T, Zamora NV, Christensen R, Suarez-Almazor ME.

J Rheumatol. 2019 Sep;46(9):1164-1167. doi: 10.3899/jrheum.181076. Epub 2019 Mar 1.

PMID:
30824644
41.

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.

Andersen KM, Kelly A, Lyddiatt A, Bingham CO 3rd, Bykerk VP, Batterman A, Westreich J, Jones MK, Cross M, Brooks PM, March L, Shea B, Tugwell P, Simon LS, Christensen R, Bartlett SJ.

J Rheumatol. 2019 Sep;46(9):1168-1172. doi: 10.3899/jrheum.181185. Epub 2019 Feb 15.

PMID:
30770516
42.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1021-1027. doi: 10.3899/jrheum.181096. Epub 2019 Feb 15.

43.

Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development.

Humphrey-Murto S, Crew R, Shea B, Bartlett SJ, March L, Tugwell P, Maxwell LJ, Beaton D, Grosskleg S, de Wit M.

J Rheumatol. 2019 Aug;46(8):1041-1046. doi: 10.3899/jrheum.181094. Epub 2019 Feb 15.

PMID:
30770512
44.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit M, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.

45.

Continuation or deprescribing of proton pump inhibitors: A consult patient decision aid.

Thompson W, Farrell B, Welch V, Tugwell P, Way C, Richardson L, Bjerre LM.

Can Pharm J (Ott). 2018 Dec 17;152(1):18-22. doi: 10.1177/1715163518816719. eCollection 2019 Jan-Feb. No abstract available.

46.

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.

Toupin-April K, Barton JL, Fraenkel L, Meara A, Li LC, Brooks P, de Wit M, Stacey D, Légaré F, Shea B, Lyddiatt A, Hofstetter C, Christensen R, Scholte Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Jull JE, Campbell W, Alten R, Karuranga S, Morgan EM, Kelly A, Kaufman J, Hill S, Maxwell LJ, Beaton D, El-Miedany Y, Mittoo S, Bartlett SJ, Singh JA, Tugwell PS.

J Rheumatol. 2019 Oct;46(10):1409-1414. doi: 10.3899/jrheum.181071. Epub 2019 Feb 1.

47.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1028-1035. doi: 10.3899/jrheum.181218. Epub 2019 Feb 1.

48.

Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health.

Milman N, McConville E, Robson JC, Boonen A, Tugwell P, Wells GA, Chaudhuri D, Dawson J, Tomasson G, Ashdown S, Gebhart D, Lanier G, Peck J, McAlear CA, Kellom KS, Cronholm PF, Merkel PA.

J Rheumatol. 2019 Oct;46(10):1415-1420. doi: 10.3899/jrheum.181073. Epub 2019 Feb 1.

PMID:
30709951
49.

Noblesse oblige: critical issues at the highest level of clinical evidence.

Knottnerus JA, Tugwell P.

J Clin Epidemiol. 2019 Feb;106:vi-viii. doi: 10.1016/j.jclinepi.2018.12.016. No abstract available.

PMID:
30654870
50.

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.

Andersen KM, Cheah JTL, March L, Bartlett SJ, Beaton D, Bingham CO 3rd, Brooks PM, Christensen R, Conaghan PG, D'Agostino MA, de Wit M, Dueck AC, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS.

J Rheumatol. 2019 Aug;46(8):1053-1058. doi: 10.3899/jrheum.181123. Epub 2019 Jan 15.

Supplemental Content

Loading ...
Support Center